In this study, we used the HER2 over-expressing breast cancer cell line, BT474 and a lapatinib resistant derivative (BT474 LapR), in an effort to investigate the functional outcome of FOXO3 acetylation as well as the role of FOXO3 acetylation in modulating lapatinib response. This evidence concerns the gene FOXO3 and breast cancer.